[Clinical efficacy of eiconol in patients with diabetic retinopathy].
Eiconol, a nutrient additive from sea fish oil, was used in the treatment of 48 patients with diabetic retinopathy. Eiconol normalized lipid metabolism parameters, which were increased, in 79.2% patients: total cholesterol decreased by 19.1%, triglycerides by 27.8%, beta-lipoproteins by 12% vs. the initial level; 74.6% patients developed favorable shifts in the status of the hemoretinal barrier and ocular microcirculation mainly at the expense of improving blood rheology. This resulted in a decrease of the recovery coefficient in photostress test by 23 +/- 1.3%. The therapeutic effect of eiconol was particularly evident during the preclinical and initial stages of manifest diabetic retinopathy and decreased as the diseases augmented in severity. Eiconol monotherapy may be recommended for correction of lipid metabolism and of functional disorders of permeability at the level of vascular and tissue membranes, and for improving the blood rheology during the preclinical stage of diabetic retinopathy. In proliferative diabetic retinopathy it is advisable to add eiconol to a complex of pathogenetic therapy.
Sorokin
E L
EL
MNTK "Microsurgery of Eye", Khabarovsk.
Smoliakova
G P
GP
Bachaldin
I L
IL
D000328:Adult; D000368:Aged; D018916:Blood-Aqueous Barrier / Q000187:drug effects / Q000502:physiology; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000378:metabolism; D004042:Dietary Fats, Unsaturated / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D005395:Fish Oils / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D012160:Retina / Q000187:drug effects; D016896:Treatment Outcome; D014792:Visual Acuity
D004042:Dietary Fats, Unsaturated; D005395:Fish Oils; D000960:Hypolipidemic Agents; D008055:Lipids; C089938:eiconol